Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis
Shannon Telesco(Janssen (United States)), Linda E. Greenbaum(Novartis (United States)), Abhijit Mazumder(Janssen (Belgium)), Walter Reinisch(Medical University of Vienna), Frédéric Baribaud(Janssen (United States)), Bethany Paxson(Janssen (United States)), Carrie Brodmerkel(Janssen (United States)), William J. Sandborn(University of San Diego), Katherine Li(Janssen (United States)), Lilianne Kim(Janssen (United States)), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Corey A. Siegel(Dartmouth–Hitchcock Medical Center), Laura A. Knight(Almac (United Kingdom)), Paul Rutgeerts(KU Leuven), Mark Curran(Janssen (United States)), Timothy S. Davison, Scott E. Plevy(Protagonist Therapeutics (United States)), Jewel Johanns(Johnson & Johnson (United States)), Richard Strauß(Hennepin County Medical Center), Hongyan Zhang(Northwest A&F University), Siân Dibben(Almac (United Kingdom))
Cited by 73
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k